FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Esteban Cvitkovic

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Katherine S Lovejoy; Eric Raymond; Maria Serova; Ivan Bieche; Massimo Broggini; Esteban Cvitkovic; Maurizio D'Incalci; Shahin Emami; Eugenio Erba; Sandrine Faivre; Christian Gespach; Stephen J Lippard
Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells.
Maria Serova; Ivan Bieche; M-P Sablin; G J Pronk; Michel Vidaud; Esteban Cvitkovic; Sandrine Faivre; Eric Raymond
Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.
Aïda Ghoul; Maria Serova; Lucile Astorgues-Xerri; Ivan Bieche; Guilhem Bousquet; Mariana Varna; Michel Vidaud; Edelmira Phillips; Sophie Weill; Karim Benhadji; François Lokiec; Esteban Cvitkovic; Sandrine Faivre; Eric Raymond
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Esteban Cvitkovic (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Katherine S Lovejoy; Eric Raymond; Maria Serova; Ivan Bieche; Massimo Broggini; Esteban Cvitkovic; Maurizio D'Incalci; Shahin Emami; Eugenio Erba; Sandrine Faivre; Christian Gespach; Stephen J Lippard
Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells.
Molecular cancer therapeutics 2011;10(9):1709-19.
2011: Maria Serova; Ivan Bieche; M-P Sablin; G J Pronk; Michel Vidaud; Esteban Cvitkovic; Sandrine Faivre; Eric Raymond
Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.
British journal of cancer 2011;104(2):272-80.
2009: Aïda Ghoul; Maria Serova; Lucile Astorgues-Xerri; Ivan Bieche; Guilhem Bousquet; Mariana Varna; Michel Vidaud; Edelmira Phillips; Sophie Weill; Karim Benhadji; François Lokiec; Esteban Cvitkovic; Sandrine Faivre; Eric Raymond
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.
Cancer research 2009;69(10):4260-9.
2008: Karim Benhadji; Maria Serova; A Ghoul; Esteban Cvitkovic; Christophe Le Tourneau; Steven M Ogbourne; François Lokiec; Fabien Calvo; Pascal Hammel; Sandrine Faivre; Eric Raymond
Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.
British journal of cancer 2008;99(11):1808-15.
2008: Maria Serova; Aïda Ghoul; Karim Benhadji; Sandrine Faivre; Christophe Le Tourneau; Esteban Cvitkovic; François Lokiec; Janet Lord; Steven M Ogbourne; Fabien Calvo; Eric Raymond
Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells.
Molecular cancer therapeutics 2008;7(4):915-22.
2007: Jérôme Alexandre; Carmen Kahatt; Frédérique Bertheault-Cvitkovic; Sandrine Faivre; Stephen Shibata; Werner Hilgers; François Goldwasser; François Lokiec; Eric Raymond; Garry Weems; Ajit Shah; John R MacDonald; Esteban Cvitkovic
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
Investigational new drugs 2007;25(5):453-62.
2007: Maria Serova; Carlos Galmarini; A Ghoul; Karim Benhadji; S R Green; J Chiao; Sandrine Faivre; Esteban Cvitkovic; Christophe Le Tourneau; Fabien Calvo; Eric Raymond
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
British journal of cancer 2007;97(5):628-36.
2006: Angelo Paci; Keyvan Rezai; Alain Deroussent; Dominique de Valeriola; Micheline Re; Sophie Weill; Esteban Cvitkovic; Carmen Kahatt; Ajit Shah; Stephen Waters; Gary Weems; Gilles Vassal; François Lokiec
Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(11):1918-26.
2006: Thierry Delozier; Jean-Paul Guastalla; Alejandro Yovine; Christelle Levy; Philippe Chollet; Mireille Mousseau; Rémi Delva; David Coeffic; Jean-Michel Vannetzel; Eliette-Sudriez Zazzi; Silvano Brienza; Esteban Cvitkovic
A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
Anti-cancer drugs 2006;17(9):1067-73.
2006: Maria Serova; Aïda Ghoul; Karim Benhadji; Esteban Cvitkovic; Sandrine Faivre; Fabien Calvo; François Lokiec; Eric Raymond
Preclinical and clinical development of novel agents that target the protein kinase C family.
Seminars in oncology 2006;33(4):466-78.
2006: Werner Hilgers; Sandrine Faivre; Stéphanie Chieze; Jérôme Alexandre; François Lokiec; François Goldwasser; Eric Raymond; Carmen Kahatt; Abdelkrim Taamma; Garry Weems; John R MacDonald; Jean-Louis Misset; Esteban Cvitkovic
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
Investigational new drugs 2006;24(4):311-9.
2006: Maria Serova; Fabien Calvo; François Lokiec; Florence Koeppel; Virginie Poindessous; Annette K Larsen; Emily S Van Laar; Stephen J Waters; Esteban Cvitkovic; Eric Raymond
Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Cancer chemotherapy and pharmacology 2006;57(4):491-9.
2006: Emmanuel Mitry; Michel Ducreux; Mahmoud Ould-Kaci; Valérie Boige; Jean-François Seitz; Roland Bugat; Jean-Luc Breau; Olivier Bouché; Pierre-Luc Etienne; Jean-Marie Tigaud; François Morvan; Esteban Cvitkovic; Philippe Rougier
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.
Gastroentérologie clinique et biologique 2006;30(3):357-63.
2006: Thierry Petit; Abdellatif Benider; Alejandro Yovine; Philippe Bougnoux; Dominique Spaeth; Frédérique Maindrault-Goebel; Daniel Serin; Jean-Dominique Tigaud; Jean-Christophe Eymard; Hélène Simon; Brigitte Bertaux; Silvano Brienza; Esteban Cvitkovic
Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline- and taxane-pre-treated metastatic breast cancer.
Anti-cancer drugs 2006;17(3):337-43.
2006: Patrice Viens; T Petit; Alejandro Yovine; Philippe Bougnoux; G Deplanque; Paul-Henri Cottu; Rémi Delva; Jean-Pierre Lotz; S V Belle; Jean-Marc Extra; Esteban Cvitkovic
A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(3):429-36.
2004: Eric Raymond; Carmen Kahatt; Marie-Hélène Rigolet; William Sutherland; François Lokiec; Jérôme Alexandre; Bertrand Tombal; Michael Elman; Michael S Lee; John R MacDonald; Michael Cullen; Jean-Louis Misset; Esteban Cvitkovic
Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(22):7566-74.
2004: Jérôme Alexandre; Eric Raymond; Mahmoud Ould Kaci; Etienne Brain; François Lokiec; Carmen Kahatt; Sandrine Faivre; Alejandro Yovine; François Goldwasser; Sheri L Smith; John R MacDonald; Jean-Louis Misset; Esteban Cvitkovic
Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3377-85.
2004: Michel Ducreux; Emmanuel Mitry; Mahmoud Ould-Kaci; Valérie Boige; Jean-François Seitz; Roland Bugat; J L Breau; Olivier Bouché; Pierre-Luc Etienne; Jean-Marie Tigaud; François Morvan; Esteban Cvitkovic; Philippe Rougier
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(3):467-73.
2004: Alejandro Yovine; M Riofrio; Jean-Yves Blay; Etienne Brain; Jérôme Alexandre; Carmen Kahatt; Abdelkrim Taamma; José Jimeno; C Martin; Y Salhi; Esteban Cvitkovic; Jean-Louis Misset
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):890-9.
2003: Catalin Mita; Etienne Chatelut; M Bekradda; Patrick Soulié; Pierre Canal; Jean-Louis Misset; Esteban Cvitkovic; Roland Bugat
Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1776-82.
2003: Virginie Poindessous; Florence Koeppel; Eric Raymond; Esteban Cvitkovic; Stephen J Waters; Annette K Larsen
Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
International journal of oncology 2003;23(5):1347-55.
2003: J P Droz; X Muracciole; N Mottet; Mahmoud Ould-Kaci; Jean-Michel Vannetzel; N Albin; Stéphane Culine; J-M Rodier; Jean-Louis Misset; S Mackenzie; Esteban Cvitkovic; G Benoit
Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(8):1291-8.
2003: Saïk Urien; Jérôme Alexandre; Eric Raymond; Etienne Brain; S Smith; A Shah; Esteban Cvitkovic; François Lokiec
Phase I population pharmacokinetics of irofulven.
Anti-cancer drugs 2003;14(5):353-8.
2002: Christophe Louvet; Thierry André; Jean-Marie Tigaud; Erick Gamelin; Jean-Yves Douillard; R Brunet; Eric François; Jacques-Henri Jacob; D Levoir; Abdelkrim Taamma; Philippe Rougier; Esteban Cvitkovic; Aimery de Gramont
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(23):4543-8.
2002: Jean-Marie Gornet; Eric Savier; François Lokiec; Esteban Cvitkovic; Jean-Louis Misset; François Goldwasser
Exacerbation of oxaliplatin neurosensory toxicity following surgery.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(8):1315-8.
2002: Michèle Boisdron-Celle; C Craipeau; Silvano Brienza; Rémi Delva; Véronique Guérin-Meyer; Esteban Cvitkovic; Erick Gamelin
Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.
Cancer chemotherapy and pharmacology 2002;49(3):235-43.
2002: Eric Raymond; Sandrine Faivre; Stephen G Chaney; Jan Woynarowski; Esteban Cvitkovic
Cellular and molecular pharmacology of oxaliplatin.
Molecular cancer therapeutics 2002;1(3):227-35.
2002: I Monnet; Cremoux H de; Patrick Soulié; S Saltiel-Voisin; M Bekradda; JC Saltiel; Etienne Brain; Olivier Rixe; Y Yataghene; Jean-Louis Misset; Esteban Cvitkovic
Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(1):103-7.
2001: Charlotte van Kesteren; R A Mathĵt; Luis López-Lázaro; Esteban Cvitkovic; Abdelkrim Taamma; José Jimeno; Cecilia Guzman; J H M Schellens; Jean-Louis Misset; Etienne Brain; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
Cancer chemotherapy and pharmacology 2001;48(6):459-66.
2001: Rolf W Sparidans; Hilde Rosing; Michel J X Hillebrand; Luis López-Lázaro; José Jimeno; Ignasio Manzanares; Charlotte van Kesteren; Esteban Cvitkovic; A T van Oosterom; J H M Schellens; Jos H Beijnen
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.
Anti-cancer drugs 2001;12(8):653-66.
2001: MA Bensmaïne; Michel Marty; A de Gramont; Silvano Brienza; Francis Lévi; M Ducreux; Eric François; Erick Gamelin; Harry Bleiberg; Esteban Cvitkovic
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
British journal of cancer 2001;85(4):509-17.
2001: A Laadem; Esteban Cvitkovic
[Oxaliplatin: a first DACH-platinum in oncology].
Bulletin du cancer 2001;88 Spec No():S9-13.
2001: Abdelkrim Taamma; Jean-Louis Misset; M Riofrio; Cecilia Guzman; Etienne Brain; Luis Lopez-Lazaro; Hilde Rosing; José Jimeno; Esteban Cvitkovic
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1256-65.
2001: Suzette Delaloge; Alejandro Yovine; Abdelkrim Taamma; M Riofrio; Etienne Brain; Eric Raymond; Paul-Henri Cottu; François Goldwasser; José Jimeno; Jean-Louis Misset; Michel Marty; Esteban Cvitkovic
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1248-55.
2001: I Monnet; Patrick Soulié; H de Cremoux; S Saltiel-Voisin; M Bekradda; JC Saltiel; Etienne Brain; G Dupont-André; Esteban Cvitkovic
Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):458-63.
2000: Ali Hasbini; Eric Raymond; Esteban Cvitkovic; François Eschwège; Jean-Pierre Armand
[Carcinoma of the nasopharynx].
Bulletin du cancer 2000;Suppl 5():21-6.
2000: Suzette Delaloge; A Laadem; Abdelkrim Taamma; N Chouaki; Esteban Cvitkovic; Patricia Pautier; Jean-Louis Misset; C Lhommé
Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer.
American journal of clinical oncology 2000;23(6):569-74.
2000: Charlotte van Kesteren; Esteban Cvitkovic; Abdelkrim Taamma; Luis López-Lázaro; José Jimeno; Cecilia Guzman; R A Math t; J H M Schellens; Jean-Louis Misset; Etienne Brain; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4725-32.
2000: Ali Hasbini; Catherine Durdux; Sandrine Faivre; E Wasserman; Abdelkrim Taamma; Jean-Pierre Armand; Eric Raymond; Esteban Cvitkovic
[Epidermoid carcinoma of the head and neck: contribution of chemotherapy in case of recurrence and locally advanced disease. Review of the literature].
Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris 2000;117(6):390-402.
2000: A de Gramont; Silvano Brienza; Michel Marty; Francis Lévi; M Ducreux; Eric François; Erick Gamelin; Harry Bleiberg; P Bleuzen; J Simon; Esteban Cvitkovic
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2335-43.
2000: François Goldwasser; Marine Gross-Goupil; Jean-Marie Tigaud; Mario Di Palma; J Marceau-Suissa; E Wasserman; Alejandro Yovine; Jean-Louis Misset; Esteban Cvitkovic
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(11):1463-70.
2000: Jean-Louis Misset; H Bleiberg; W Sutherland; M Bekradda; Esteban Cvitkovic
Oxaliplatin clinical activity: a review.
Critical reviews in oncology/hematology 2000;35(2):75-93.
2000: Karim Fizazi; Raffaele Caliandro; Patrick Soulié; A Fandi; C Daniel; A Bedin; H Doubre; Juliette Viala; Jean-François Rodier; L Trandafir; Thierry Le Chevalier; Esteban Cvitkovic; Jean-Pierre Armand; Pierre Ruffié
Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma.
European journal of cancer (Oxford, England : 1990) 2000;36(12):1514-21.
2000: A Fandi; M Bachouchi; Nacer Azli; Abdelkrim Taamma; H Boussen; Pierre Wibault; François Eschwege; Jean-Pierre Armand; J Simon; Esteban Cvitkovic
Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1324-30.
2000: Jérôme Alexandre; P Bleuzen; Jacques Bonneterre; W Sutherland; Jean-Louis Misset; Jean-Paul Guastalla; Patrice Viens; Sandrine Faivre; A Chahine; M Spielman; A Bensmaïne; Michel Marty; Mondher Mahjoubi; Esteban Cvitkovic
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):562-73.
1999: Esteban Cvitkovic; M Bekradda
Oxaliplatin: a new therapeutic option in colorectal cancer.
Seminars in oncology 1999;26(6):647-62.
1999: Patrick Soulié; C Garrino; MA Bensmaïne; M Bekradda; Etienne Brain; Mario Di Palma; A Goupil; Jean-Louis Misset; Esteban Cvitkovic
Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Journal of cancer research and clinical oncology 1999;125(12):707-11.
1999: Silvano Brienza; MA Bensmaïne; Patrick Soulié; C Louvet; Erick Gamelin; Eric François; M Ducreux; Michel Marty; Thierry André; F de Braud; Harry Bleiberg; V Ségal; M Itzhaki; Esteban Cvitkovic
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1311-6.
1999: Abdelkrim Taamma; A Fandi; Nacer Azli; Pierre Wibault; N Chouaki; Ali Hasbini; Corinne Couteau; Jean-Pierre Armand; Esteban Cvitkovic
Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type.
Cancer 1999;86(7):1101-8.
1999: Sandrine Faivre; S Kalla; Esteban Cvitkovic; O Bourdon; D Hauteville; L M Dourte; MA Bensmaïne; M Itzhaki; Michel Marty; Jean-Marc Extra
Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(9):1125-8.
1999: E Wasserman; Caroline Cuvier; François Lokiec; François Goldwasser; S Kalla; Dominique Méry-Mignard; M Ouldkaci; A Besmaine; G Dupont-André; Mondher Mahjoubi; Michel Marty; Jean-Louis Misset; Esteban Cvitkovic
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1751-9.
1999: Jean-Louis Misset; Véronique Dieras; G Gruia; Hugues Bourgeois; Esteban Cvitkovic; S Kalla; Laurence Bozec; Philippe Beuzeboc; Claude Jasmin; J P Aussel; A Riva; Nacer Azli; Pierre Pouillart
Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):553-60.
1999: Ali Hasbini; R Mahjoubi; A Fandi; N Chouaki; Abdelkrim Taamma; P Lianes; H Cortès-Funes; S Alonso; Jean-Pierre Armand; Esteban Cvitkovic; Eric Raymond
Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):421-5.
1999: N Germann; Silvano Brienza; M Rotarski; Jean-François Emile; Mario Di Palma; M Musset; M Reynes; Patrick Soulié; Esteban Cvitkovic; Jean-Louis Misset
Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(3):351-4.
1999: François Goldwasser; X Buthaud; M Gross; P Bleuzen; Esteban Cvitkovic; A Voinea; C Jasmin; Didier Romain; Jean-Louis Misset
Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients.
Anti-cancer drugs 1999;10(3):263-5.
1999: M Bekradda; Esteban Cvitkovic
New possibilities in chemotherapy for colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 6():105-11.
1999: Sandrine Faivre; Eric Raymond; Jan Woynarowski; Esteban Cvitkovic
Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.
Cancer chemotherapy and pharmacology 1999;44(2):117-23.
1998: Jérôme Alexandre; Sandrine Faivre; W Sutherland; Esteban Cvitkovic
Effects of adjuvant chemotherapy on the natural history and likelihood of therapeutic efficacy in advanced breast cancer patients: a critical literature review.
Cancer treatment reviews 1998;24(6):393-406.
1998: Hilde Rosing; Michel J X Hillebrand; José Jimeno; A Gómez; Pablo Floriano; Glynn Faircloth; RE Henrar; Jan B Vermorken; Esteban Cvitkovic; Auke Bult; Jos H Beijnen
Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 1998;33(11):1134-40.
1998: Eric Raymond; Stephen G Chaney; Abdelkrim Taamma; Esteban Cvitkovic
Oxaliplatin: a review of preclinical and clinical studies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(10):1053-71.
1998: Faouzi Saliba; R Hagipantelli; Jean-Louis Misset; Gérard Bastian; Gilles Vassal; Marc Bonnay; P Herait; C Cote; Mondher Mahjoubi; Dominique Mignard; Esteban Cvitkovic
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2745-51.
1998: Esteban Cvitkovic; Michel Marty; E Wasserman; Caroline Cuvier; François Goldwasser; Jean-Louis Misset
Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Journal of the National Cancer Institute 1998;90(13):1016-7.
1998: I Monnet; Silvano Brienza; F Hugret; S Voisin; J Gastiaburu; JC Saltiel; Patrick Soulié; Jean-Pierre Armand; Esteban Cvitkovic; H de Cremoux
Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques.
European journal of cancer (Oxford, England : 1990) 1998;34(7):1124-7.
1998: Laurence Bozec; Philippe Bierling; Patricia Fromont; F Lévi; P Debat; Esteban Cvitkovic; Jean-Louis Misset
Irinotecan-induced immune thrombocytopenia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(4):453-5.
1998: Michel Ducreux; Christophe Louvet; M Bekradda; Esteban Cvitkovic
Oxaliplatin for the treatment of advanced colorectal cancer: future directions.
Seminars in oncology 1998;25(2 Suppl 5):47-53.
1998: Esteban Cvitkovic
A historical perspective on oxaliplatin: rethinking the role of platinum compounds and learning from near misses.
Seminars in oncology 1998;25(2 Suppl 5):1-3.
1998: Erick Gamelin; Michèle Boisdron-Celle; A Lebouil; Alain Turcant; A Cailleux; A Krikorian; Silvano Brienza; Esteban Cvitkovic; F Larra; J Robert; P Allain
Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters.
Anti-cancer drugs 1998;9(3):223-8.
1997: L Trandafir; Pierre Ruffié; C Borel; I Monnet; Patrick Soulié; david adams; Esteban Cvitkovic; Jean-Pierre Armand
Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma.
European journal of cancer (Oxford, England : 1990) 1997;33(11):1900-2.
1997: Eric Raymond; C Buquet-Fagot; S Djelloul; Jan Mester; Esteban Cvitkovic; P Allain; Christophe Louvet; Christian Gespach
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
Anti-cancer drugs 1997;8(9):876-85.
1997: E Wasserman; Anne Myara; François Lokiec; François Goldwasser; François Trivin; Mondher Mahjoubi; Jean-Louis Misset; Esteban Cvitkovic
Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):1049-51.
1997: Patrick Soulié; L Trandafir; Abdelkrim Taamma; François Lokiec; Etienne Brain; Jean-Pierre Delord; Catalin Mita; Jean-Michel Vannetzel; Esteban Cvitkovic; Jean-Louis Misset
Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer.
Anti-cancer drugs 1997;8(8):763-6.
1997: Patrick Soulié; A Bensmaïne; C Garrino; Philippe Chollet; Etienne Brain; M Fereres; C Jasmin; M Musset; Jean-Louis Misset; Esteban Cvitkovic
Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
European journal of cancer (Oxford, England : 1990) 1997;33(9):1400-6.
1997: Erick Gamelin; A L Bouil; Michèle Boisdron-Celle; Alain Turcant; Rémi Delva; A Cailleux; A Krikorian; Silvano Brienza; Esteban Cvitkovic; J Robert; F Larra; P Allain
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(6):891-9.
1997: Patrick Soulié; E Raymond; Silvano Brienza; Esteban Cvitkovic
[Oxaliplatin: the first DACH platinum in clinical practice].
Bulletin du cancer 1997;84(6):665-73.
1997: Etienne Brain; Catalin Mita; Patrick Soulié; H Errihani; A C Hardy Bessard; M Chaouche; Jérôme Alexandre; Jean-Pierre Delord; Esteban Cvitkovic; C Jasmin; Jean-Louis Misset
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.
Journal of cancer research and clinical oncology 1997;123(4):227-31.
1997: Esteban Cvitkovic
A call for change in anticancer drug evaluation.
European journal of cancer (Oxford, England : 1990) 1997;33 Suppl 2():S3-7.
1997: Etienne Brain; C Garrino; Jean-Louis Misset; I G Carbonero; M Itzhaki; Esteban Cvitkovic; E Goldschmidt; F Burki; C Regensberg; E Pappo; R Hagipantelli; M Musset
Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
British journal of cancer 1997;75(9):1360-7.
1997: A Fandi; Abdelkrim Taamma; Nacer Azli; M Bachouchi; B Yanes; Jean-Pierre Armand; Esteban Cvitkovic
Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type.
Head & neck 1997;19(1):41-7.
1996: Philippe Chollet; MA Bensmaïne; Silvano Brienza; C Deloche; Hervé Curé; H Caillet; Esteban Cvitkovic
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(10):1065-70.
1996: T Guillot; E T Bernal; François Janot; Robert Sigal; Christian Domenge; Pierre Wibault; Jean-Pierre Armand; Esteban Cvitkovic
Neoadjuvant chemotherapy with cisplatin-vindesine-5-fluorouracil and folinic acid for locally advanced head and neck carcinoma.
American journal of clinical oncology 1996;19(4):356-62.
1996: M E Bensmaine; Nacer Azli; Christian Domenge; Jean-Pierre Armand; Esteban Cvitkovic
Phase I-II trial of recombinant interferon alpha-2b with cisplatin and 5-fluorouracil in recurrent and/or metastatic carcinoma of head and neck.
American journal of clinical oncology 1996;19(3):249-54.
1996: Pierre Wibault; M A Bensmaine; M de Forni; Jean-Pierre Armand; E Tellez Bernal; T Guillot; G Recondo; Christian Domenge; François Janot; C Borel; Bernard Luboinski; François Eschwege; Esteban Cvitkovic
Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1192-200.
1996: Patrick Soulié; Pierre Ruffié; L Trandafir; I Monnet; Anne Tardivon; Philippe Terrier; Esteban Cvitkovic; Thierry Le Chevalier; Jean-Pierre Armand
Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):878-85.
1996: François Janot; J Klijanienko; A Russo; J P Mamet; F de Braud; Adel K El-Naggar; J P Pignon; Bernard Luboinski; Esteban Cvitkovic
Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis.
British journal of cancer 1996;73(4):531-8.
1995: Nacer Azli; A Fandi; M Bachouchi; mohamed rahal; P Lianes; Pierre Wibault; H Boussen; François Eschwege; Jean-Pierre Armand; Esteban Cvitkovic
Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
The cancer journal from Scientific American 1995;1(3):222-9.
1995: A Fandi; Esteban Cvitkovic
Biology and treatment of nasopharyngeal cancer.
Current opinion in oncology 1995;7(3):255-63.
1995: J Klijanienko; Adel K El-Naggar; F de Braud; J L Rodriguez-Peralto; R Rodriguez; M Itzhaki; A Russo; François Janot; Bernard Luboinski; Esteban Cvitkovic
Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas.
Cancer 1995;75(7):1649-56.
1994: A Fandi; B Yanes; Abdelkrim Taamma; Nacer Azli; Jean-Pierre Armand; O Dupuis; François Eschwège; Guy Schwaab; Esteban Cvitkovic
[Undifferentiated carcinoma of the nasopharynx: epidemiological, clinical and therapeutic aspects].
Bulletin du cancer 1994;81(7):571-86.
1994: A Fandi; Musa Altun; Nacer Azli; Jean-Pierre Armand; Esteban Cvitkovic
Nasopharyngeal cancer: epidemiology, staging, and treatment.
Seminars in oncology 1994;21(3):382-97.
1994: Marc Spielmann; Daniel Gandía; Karim Fizazi; T Guillot; Esteban Cvitkovic; L Kayitalire; T Girinsky; Dominique Elias; Philippe Rougier; J Kac
Phase II study of 4'epirubicin in advanced squamous cell oesophageal cancer.
European journal of cancer (Oxford, England : 1990) 1994;30A(12):1908-9.
1993: Esteban Cvitkovic; M Bachouchi; H Boussen; Pierre Busson; G Rousselet; R Mahjoubi; P Flores; Thomas Tursz; Jean-Pierre Armand; Nacer Azli
Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(12):2434-42.
1993: G Rousselet; M Bachouchi; Pierre Busson; Florent de Vathaire; H Wakasugi; Guy Schwaab; Nacer Azli; Jean-Pierre Armand; Esteban Cvitkovic; Thomas Tursz
Clinical implications of the serum level of CD23 in patients with undifferentiated nasopharyngeal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2143-9.
1993: J Klijanienko; Adel El-Naggar; F De Braud; C Micheau; François Janot; Bernard Luboinski; A Gentile; A Russo; Esteban Cvitkovic
Keratins 6, 13 and 19. Differential expression in squamous cell carcinoma of the head and neck.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 1993;15(5):335-40.
1993: Jean-Pierre Armand; Esteban Cvitkovic; G Recondo; Pierre Wibault; Guy Schwaab; Christian Domenge; E Tellez-Bernal; Daniel Gandía; Bernard Luboinski; François Eschwege
Salvage chemotherapy in recurrent head and neck cancer: the Institut Gustave Roussy experience.
American journal of otolaryngology 1993;14(5):301-6.
1993: Esteban Cvitkovic; Christian Domenge; Daniel Gandía
Case report of acquired piritrexim resistance and collateral methotrexate sensitivity in recurrent squamous cell carcinoma of the head and neck.
Journal of the National Cancer Institute 1993;85(15):1248.
1993: François Janot; Esteban Cvitkovic; J D Piekarski; Robert Sigal; Jean-Pierre Armand; A Bensmaine; Bernard Luboinski
Correlation between nodal density in contrasted scans and response to cisplatin-based chemotherapy in head and neck squamous cell cancer: a prospective validation.
Head & neck 1993;15(3):222-9.
1993: Philippe Rougier; J J Zarba; Michel Ducreux; M Basile; Jean-Pierre Pignon; Mondher Mahjoubi; M Benahmed; Jean Pierre Droz; Esteban Cvitkovic; Jean-Pierre Armand
Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(4):333-6.
1993: R Mahjoubi; M Bachouchi; Jean-Nicolas Munck; Pierre Busson; J Gasmi; Nacer Azli; M Brandely; T Trusz; Esteban Cvitkovic; Jean-Pierre Armand
Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx.
Head & neck 1993;15(2):115-8.
1993: M Riggi; Esteban Cvitkovic; H de Cremoux; P Ruffie; I Monnet; S Voisin; W Villalobos; N Azli; J C Saltiel
Cisplatin and continuous infusion vindesine and 5-fluorouracil in non-small cell lung cancer (NSCLC) (ATTIT 002). ATTIT (Association pour le Traitment des Tumeurs Intra-Thoraciques)
European journal of cancer (Oxford, England : 1990) 1993;29A(13):1914-5.
1993: Daniel Gandía; Pierre Wibault; T Guillot; A Bensmaine; Jean-Pierre Armand; Patrick Marandas; Bernard Luboinski; Esteban Cvitkovic
Simultaneous chemoradiotherapy as salvage treatment in locoregional recurrences of squamous head and neck cancer.
Head & neck 1993;15(1):8-15.
1992: T Guillot; Marc Spielmann; J Kac; Bernard Luboinski; E Tellez-Bernal; Jean-Nicolas Munck; M Bachouchi; Jean-Pierre Armand; Esteban Cvitkovic
Neoadjuvant chemotherapy in multiple synchronous head and neck and esophagus squamous cell carcinomas.
The Laryngoscope 1992;102(3):311-9.
1992: Nacer Azli; Jean-Pierre Armand; mohamed rahal; Pierre Wibault; H Boussen; François Eschwege; Guy Schwaab; J Gasmi; M Bachouchi; Esteban Cvitkovic
Alternating chemo-radiotherapy with cisplatin and 5-fluorouracil plus bleomycin by continuous infusion for locally advanced undifferentiated carcinoma nasopharyngeal type.
European journal of cancer (Oxford, England : 1990) 1992;28A(11):1792-7.
1992: Esteban Cvitkovic; J Izzo
The current and future place of vinorelbine in cancer therapy.
Drugs 1992;44 Suppl 4():36-45; discussion 66-9.
1991: G Recondo; Esteban Cvitkovic; Nacer Azli; E Tellez Bernal; Florent de Vathaire; Pierre Wibault; J M Richard; Patrick Marandas; M Benahmed; Christian Domenge
Neoadjuvant chemotherapy consisting of cisplatin and continuous infusions of bleomycin and 5-fluorouracil for advanced head and neck cancer. The need for a new stratification for stage IV (M0) disease.
Cancer 1991;68(10):2109-19.
1991: H Boussen; Esteban Cvitkovic; J L Wendling; Nacer Azli; M Bachouchi; R Mahjoubi; Chantal Kalifa; Pierre Wibault; Guy Schwaab; Jean-Pierre Armand
Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(9):1675-81.
1991: Esteban Cvitkovic; M Bachouchi; Jean-Pierre Armand
Nasopharyngeal carcinoma. Biology, natural history, and therapeutic implications.
Hematology/oncology clinics of North America 1991;5(4):821-38.
1991: G Recondo; Jean-Pierre Armand; E Tellez-Bernal; Christian Domenge; M Belehradek; Florent de Vathaire; Pierre Wibault; J M Richard; Esteban Cvitkovic
Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.
The Laryngoscope 1991;101(5):494-501.
1991: Jean-Nicolas Munck; Esteban Cvitkovic; J D Piekarski; E Benhamou; G Recondo; M Bachouchi; E Tellez-Bernal; Bernard Luboinski; François Eschwege; Pierre Wibault
Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer.
Journal of the National Cancer Institute 1991;83(8):569-75.
1991: I Monnet; Patrick Chariot; N Azli; Pierre Ruffié; S Voisin; J C Saltiel; H de Cremoux; Esteban Cvitkovic
Severe mucositis after chemotherapy with vinorelbine, 5-fluorouracil, leucovorin and cisplatin.
European journal of cancer (Oxford, England : 1990) 1991;27(12):1716-7.
1991: M Riggi; P Ruffie; S Voisin; I Monnet; H de Cremoux; J C Saltiel; M Martin; L Vergne; J Huet; Esteban Cvitkovic
Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques).
European journal of cancer (Oxford, England : 1990) 1991;27(10):1238-42.
1990: H Sadek; Nacer Azli; J L Wendling; Esteban Cvitkovic; mohamed rahal; Gérard Mamelle; Jean-Claude Guillaume; Jean-Pierre Armand; Marie-Françoise Avril
Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin.
Cancer 1990;66(8):1692-6.
1990: E Tellez-Bernal; M Belehradek; G Recondo; Esteban Cvitkovic; Anne-Marie Leridant; R Vericel; Jean-Pierre Armand
Phase II study of cisplatin and continuous-infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous-cell carcinoma.
American journal of clinical oncology 1990;13(5):452-4.
1990: E Tellez-Bernal; G Recondo; T Guillot; M Benhamed; Christian Domenge; J Izzo; Esteban Cvitkovic; Jean-Pierre Armand
A phase II study of cisplatin and continuous infusion of vindesine in metastatic head and neck squamous cell cancer.
Cancer 1990;66(4):640-4.
1990: J Gasmi; M Bachouchi; Esteban Cvitkovic; H Boussen; Nacer Azli; mohamed rahal; Christian Domenge; Pierre Wibault; François Eschwege; Guy Schwaab
Nasopharyngeal carcinoma: a medical oncology viewpoint. The Gustave Roussy experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1990;1(4):245-53.
1990: M Bachouchi; Esteban Cvitkovic; Nacer Azli; J Gasmi; H Cortes-Funes; H Boussen; mohamed rahal; Chantal Kalifa; Guy Schwaab; François Eschwege
High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy.
Journal of the National Cancer Institute 1990;82(7):616-20.
1989: G Recondo; M Benhamed; Esteban Cvitkovic; Patrick Marandas; Jean-Pierre Armand
96-hour continuous infusion of cis-platinum, 5-fluorouracil and bleomycin in recurrent or metastatic head and neck squamous cell carcinoma, unexpected anemia.
European journal of cancer & clinical oncology 1989;25(11):1529-33.
1989: J Klijanienko; C Micheau; Nacer Azli; Esteban Cvitkovic; François Eschwege; Patrick Marandas; Jean-Pierre Armand; Odile Casiraghi; Guy Schwaab; Florent de Vathaire
Undifferentiated carcinoma of nasopharyngeal type of tonsil.
Archives of otolaryngology--head & neck surgery 1989;115(6):731-4.
1989: P Herait; Jean-Pierre Armand; M Benahmed; Christian Domenge; X Fontana; G Recondo; Esteban Cvitkovic; F M Delgado
Phase II study of mitozolomide (M & B 39,565) in head and neck cancer.
Medical oncology and tumor pharmacotherapy 1989;6(4):267-9.
1988: Jean-Pierre Armand; M De Forni; G Recondo; L Cals; Esteban Cvitkovic; Jean-Nicolas Munck
Flavonoids: a new class of anticancer agents? Preclinical and clinical data of flavone acetic acid.
Progress in clinical and biological research 1988;280():235-41.
1988: P Evenou; Esteban Cvitkovic; Gérard Mamelle; Pierre Duvillard; G Klijanienko; L Wagner; J P Noble; J L Wendling; Jean-Claude Guillaume; Marie-Françoise Avril
[Complete remission (clinical and histologic) of an advanced squamous cell epithelioma treated only by chemotherapy].
Annales de dermatologie et de vénéréologie 1988;115(12):1285-8.
1987: Philippe Rougier; Jean Pierre Droz; Christine Theodore; G Piot; P Herait; P Ruffie; P Carde; Esteban Cvitkovic
Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma.
Cancer treatment reports 1987;71(12):1301-2.
1987: C Micheau; H Boussen; J Klijanienko; Esteban Cvitkovic; S Stosic; Guy Schwaab; François Eschwege; Jean-Pierre Armand
Bone marrow biopsies in patients with undifferentiated carcinoma of the nasopharyngeal type.
Cancer 1987;60(10):2459-64.